Lucigenin Chemiluminescence Assay for Point-of-Care Neutrophil Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing automated blood analyzers are complex and not suitable for point-of-care (POC) assays, particularly for measuring phagocytic leukocytes like neutrophils, due to their morphological and functional differences, and they do not effectively quantify phagocyte function.
Innovation Solution
A chemiluminescence-based assay using lucigenin as a chemiluminigenic probe to measure NADPH oxidase-dependent reductive dioxygenation activity in diluted whole blood or body fluids, activated by a stimulus like PMA, allowing quantification of phagocyte function and absolute neutrophil count (ANC) suitable for POC testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If automated blood analyzers are used to measure leukocytes, then counting and differentiation can be achieved, but the device complexity becomes too high for point-of-care applications
Solution Approach 1:
The patent extracts the specific function of measuring phagocyte NADPH oxidase activity from the complex automated blood analyzer system. By using a simple luminometer to detect chemiluminescence signal from lucigenin oxidation, the method isolates the essential measurement function while eliminating unnecessary complexity of full automated analyzers.
Solution Approach 2:
The patent replaces the mechanical and optical systems of automated blood analyzers (impedance, light scatter, flow cytometry) with a chemical-biological assay system. The complex physical measurement systems are substituted by a biochemical reaction system where NADPH oxidase activity directly produces a measurable chemiluminescence signal.
2Quantity of substance
If conventional ANC methods are used, then neutrophil count can be obtained, but functional assessment of phagocytes is not provided
Solution Approach 1:
The patent changes the measurement parameter from simple cell counting to functional enzyme activity measurement. By measuring NADPH oxidase activity through chemiluminescence signal intensity, the method provides functional information about phagocyte respiratory burst capability while still correlating with cell count.
Solution Approach 2:
The patent introduces lucigenin as an intermediary substrate that mediates between NADPH oxidase activity and detectable signal. The chemiluminigenic probe translates the biochemical activity of NADPH oxidase into a measurable chemiluminescence signal, providing functional information that simple counting cannot capture.
3Ease of operation
If simple counting methods are used, then the assay can be performed at point-of-care, but sensitivity and functional relevance are reduced
Solution Approach 1:
The patent uses chemiluminescence amplification through lucigenin oxidation to enhance the sensitivity of the assay. The chemiluminigenic probe amplifies the weak signal from NADPH oxidase activity into a strong measurable light signal, maintaining functional assessment sensitivity while enabling simple point-of-care operation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a sensitive and clinically relevant assessment of neutrophil function and count, applicable to POC testing, with results maintained for up to 16 hours post-venipuncture, offering superior information compared to conventional ANC methods.
Implementation Method 1
measuring the reductive dioxygenation of a chemiluminigenic probe
Implementation Method 2
NADPH oxidase-dependent reductive dioxygenation activity
Data Source
AI summary
A method for estimating a number of phagocytes in a body fluid of an animal includes stimulating NADPH oxidase activity of the phagocytes; and quantifying a resulting reductive dioxygenation of a chemiluminigenic substrate by an emitted chemiluminescence of the chemiluminigenic substrate using an instrument capable of measuring light. The NADPH oxidase activity of the phagocytes is preferably stimulated by an immunologic or chemical capable of activating a respiratory burst by the phagocytes. The NADPH oxidase activity of the phagocytes is preferably stimulated by a stimulus in solution or coated to a surface contacted by the phagocytes. The stimulus is preferably phorbol myristate acetate (PMA). The animal is preferably human, and the body fluid is preferably blood and/or spinal fluid. The phagocytes are preferably neutrophil leukocytes, and the chemiluminigenic substrate is preferably lucigenin (N,N′-dimethyl-9,9′-biacridinium dinitrate). Also provided is a method of treatment based on the estimation method.